Franklin Biolabs CEO Selected as a 2026 Women of Influence by the Philadelphia Business Journal
Learn more

In Vivo Efficacy of AAV9 Vectors in Porcine Models of Duchenne Muscular Dystrophy

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

In Vivo Efficacy of AAV9 Vectors in Porcine Models of Duchenne Muscular Dystrophy

CELL & GENE | RNA | BIOLOGICS

    Why are porcine models preferred for DMD gene therapy studies?

    A: Porcine models offer superior translational relevance due to their anatomical and physiological similarity to humans. Their comparable muscle mass, body size, and cardiovascular system provide a more predictive environment for assessing AAV vector efficacy, biodistribution, and safety ahead of clinical trials.

    What are the key challenges with AAV9 tropism in large animal models?

    A: The primary challenges involve managing hepatic uptake and ensuring sufficient vector transduction of target tissues like cardiac and skeletal muscle. As demonstrated in cross-species analyses, differences in cell surface glycan presentation between species can significantly alter vector biodistribution, requiring careful capsid selection or engineering to achieve the desired therapeutic profile.

    How is efficacy measured in these preclinical studies?

    A: Efficacy is evaluated through a multi-faceted approach. This includes functional endpoints (e.g., muscle strength and motor function), comprehensive histological analysis to assess muscle fiber regeneration and morphology, and molecular biomarker quantification, such as dystrophin expression levels in target muscle tissues via Western blot or IHC.

    What is the vector manufacturing requirement for porcine studies?

    A: Due to the significant body mass of porcine models compared to smaller laboratory animals, substantially higher total vector quantities are required to achieve therapeutic dosing levels. This necessitates robust, scalable, and consistent GxP-grade vector manufacturing and analytics to support these pivotal IND-enabling studies.

Translating AAV9-based gene therapies for Duchenne Muscular Dystrophy (DMD) from small animal studies to human clinical trials requires validation in a large animal model that accurately reflects human physiology. Porcine models provide this necessary translational bridge. Success depends on a dual strategy: optimizing the AAV9 vector for maximal muscle tropism and minimal off-target effects, and executing the in vivo study with rigorous analytical endpoints. Franklin Biolabs combines expertise in vector engineering with extensive large animal model capabilities to generate the high-fidelity data packages required to support an 18-24 month IND timeline.

Translating AAV9-Mediated Dystrophin Expression to a Clinically Relevant Scale

The central challenge in advancing AAV9-based therapies for DMD is confirming that efficacy and biodistribution observed in smaller models will translate to the clinic. The porcine model is an invaluable tool for this purpose, offering a platform to de-risk clinical development by assessing vector performance in a system with human-like scale and complexity.

Executing these studies demands a sophisticated understanding of both vector biology and large animal physiology. The process requires designing a comprehensive program to measure functional outcomes, quantify transgene expression at the tissue level, and build a robust safety profile.

A blue-toned image of white lab rats in their cages within a laboratory or vivarium setting, likely for scientific research or testing.

A close-up shot of a modern bioreactor system and control unit from Pall Corporation in a clean laboratory environment.

Engineering AAV Vectors for Enhanced Muscle Tropism

Achieving therapeutic benefit in DMD hinges on efficient delivery of the dystrophin transgene to skeletal and cardiac muscle. This can be approached by refining both the delivery vehicle and its genetic payload.

  • Capsid Optimization: Research into AAV biology shows that modulating the capsid’s interaction with cell surface glycans is a powerful strategy to alter tissue tropism (PMID: 39001819). By engineering the AAV9 capsid, it is possible to detarget the liver and enhance vector delivery to muscle tissues, a key consideration for improving the safety and efficacy profile in a large animal.

  • Payload Enhancement: Beyond the capsid, the transgene itself can be engineered for superior performance. The principles of creating gain-of-function variants, as demonstrated in other therapeutic areas, can be applied to enhance the activity of the delivered protein, potentially allowing for greater efficacy at lower vector doses (PMID: 25023731).

Characterizing Biodistribution and Safety in Large Animal Models

A comprehensive non-target tissue biodistribution study is fundamental to any IND-enabling package. In our >100,000 sq ft facility, we employ a suite of validated analytical methods, including qPCR, ddPCR, and detailed Histology, to precisely quantify vector distribution and transgene expression across all relevant tissues. This granular data provides a clear picture of vector behavior and safety.

“We started collaborating with UPenn Vector core in 2023 and the AAV vector which they manufactured laid a foundation for development of a gene therapy candidate which will enter soon preclinical studies. The key people from UPenn Vector Core joined Franklin Biolabs and our partnership transitioned without interruption from UPenn Vecor Core to Franklin Biolabs Research Vector Division. Franklin Biolabs is our trusted partner in our AAV-vector based gene therapy candidate development and we hope to continue the partnership for years to come.”
— Biotech Partner

A stylized 3D rendering of a DNA double helix, composed of light-colored spheres on a translucent blue backbone, set against a soft-focus, light blue background.

Commitment to Animal Welfare and the 3Rs

Franklin Biolabs is fully committed to the highest standards of animal welfare in all research programs. Our operations adhere to AAALAC guidelines and USDA compliance, with a focus on implementing the 3Rs: Reduction, Refinement, and Replacement.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities